Sarcoma  >>  NKTR-262  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NKTR-262 / Nektar Therap
REVEAL, NCT03435640: Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Checkmark In combination with NKTR-262
Mar 2019 - Mar 2019: In combination with NKTR-262
Checkmark P1b data from P1b/2 REVEAL trial in combination with NKTR-262 at ASCO-SITC 2019 [screenshot]
Feb 2019 - Feb 2019: P1b data from P1b/2 REVEAL trial in combination with NKTR-262 at ASCO-SITC 2019 [screenshot]
Checkmark Initial data from REVEAL trial in combination with NKTR-214 and NKTR-262 in advanced solid tumor malignancies at SITC 2018
More
Terminated
1/2
64
US
NKTR-262, bempegaldesleukin, NKTR-214, nivolumab, Opdivo®
Nektar Therapeutics
Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma
05/22
05/22

Download Options